Saturday 17 October 2026
Export BLRX’s income statement to Excel — free account
BioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024. In the quarter to June 2026, revenue fell 3.29%, EPS grew 23.0%, free cash flow fell 1,827.7% and total debt fell 40.2%, each against the same quarter a year earlier.
2.04
0.01
−0.49%
Follow BLRX
BioLineRx Ltd. (BLRX) P/E ratio
BioLineRx Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| BIVI BioVie Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| TPST Tempest Therapeutics, Inc. compare | n/m |
| BLRX BioLineRx Ltd. | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| TOVX Theriva Biologics, Inc. compare | 0.1× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)